XenoTech Offers Metabolite Profiling Services Following Acquisition of Waters Synapt HDMS System
News Feb 17, 2009
Waters Corporation has announced that XenoTech (Lenexa, KS) has begun offering new metabolite profiling services made possible in part by its recent acquisition of a Waters® Synapt™ High Definition Mass Spectrometry™ (HDMS) System.
The Synapt HDMS System is the centerpiece of its metabolite profiling efforts and allows XenoTech to offer one-of-a-kind services to companies that are investigating promising new drug candidates.
Integrated with a Waters ACQUITY® UltraPerformance Liquid Chromatograph (UPLC®) the Synapt HDMS System will provide XenoTech's scientific consultants with in vitro drug metabolism study data to support its clients' drug discovery decision-making process, offering them insights into the viability of potential drug candidates prior to their introduction into clinical trials.
"We have built a high degree of quality into XenoTech's products and in vitro services," states Andrew Parkinson, CEO / CSO of XenoTech. "We enjoy a very strong reputation for drug metabolism research and for our consultative approach to contract services. Our customers know that they can expect the best from us, and in turn, we expect the best from the instrumentation that we use to investigate their compounds"
"The economic landscape comes into play as well," says Parkinson. "Customers are faced with the need to collect more information on their developmental drugs with limited budgets and reduced staff. As a provider of contract services, we must produce the most meaningful and reliable data as quickly and efficiently as possible using small amounts of costly test compounds, and offer flexibility in our study designs to achieve cost savings and provide value for money. The Waters Synapt HDMS System was a perfect fit for both our scientific expectations and our operational requirements."
XenoTech purchased the Waters Synapt HDMS System after an exhaustive six-month evaluation of the offerings of all commercial instrument providers.
"We needed flawless high resolution and accurate mass," said Paul Toren, Director of Drug Metabolism and Analytical Chemistry at XenoTech. "We were impressed with the integrated software and work-flow, and once we saw the added capabilities of the Synapt HDMS's ion mobility feature, we were convinced that this was the instrument for XenoTech's lab."
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE